Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center.

Lee TW, Brownlee KG, Denton M, Littlewood JM, Conway SP.

Pediatr Pulmonol. 2004 Feb;37(2):104-10.

PMID:
14730654
2.

Eradication of early Pseudomonas aeruginosa infection.

Høiby N, Frederiksen B, Pressler T.

J Cyst Fibros. 2005 Aug;4 Suppl 2:49-54. Review.

3.

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.

Langton Hewer SC, Smyth AR.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD004197. doi: 10.1002/14651858.CD004197.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;11:CD004197.

PMID:
19821321
4.

The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?

Banerjee D, Stableforth D.

Drugs. 2000 Nov;60(5):1053-64. Review.

PMID:
11129122
5.

Bronchoscopy-guided antimicrobial therapy for cystic fibrosis.

Jain K, Wainwright C, Smyth AR.

Cochrane Database Syst Rev. 2013 Dec 23;(12):CD009530. doi: 10.1002/14651858.CD009530.pub2. Review. Update in: Cochrane Database Syst Rev. 2016;(1):CD009530.

PMID:
24363033
6.

Bronchoscopy-guided antimicrobial therapy for cystic fibrosis.

Jain K, Wainwright C, Smyth AR.

Cochrane Database Syst Rev. 2016 Jan 21;(1):CD009530. doi: 10.1002/14651858.CD009530.pub3. Review.

PMID:
26797965
7.

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.

Wood DM, Smyth AR.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004197. Review. Update in: Cochrane Database Syst Rev. 2009;(4):CD004197.

PMID:
16437476
9.

Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis.

Langan KM, Kotsimbos T, Peleg AY.

Curr Opin Infect Dis. 2015 Dec;28(6):547-56. doi: 10.1097/QCO.0000000000000217. Review. Erratum in: Curr Opin Infect Dis. 2016 Feb;29(1):98.

PMID:
26524327
10.

The Approach to Pseudomonas aeruginosa in Cystic Fibrosis.

Talwalkar JS, Murray TS.

Clin Chest Med. 2016 Mar;37(1):69-81. doi: 10.1016/j.ccm.2015.10.004. Review.

PMID:
26857769
11.

Changes in strategies for optimal antibacterial therapy in cystic fibrosis.

Ratjen F.

Int J Antimicrob Agents. 2001 Feb;17(2):93-6. Review.

PMID:
11165111
12.

Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.

Cantón R, Cobos N, de Gracia J, Baquero F, Honorato J, Gartner S, Alvarez A, Salcedo A, Oliver A, García-Quetglas E; Spanish Consensus Group for Antimicrobial Therapy in the Cystic Fibrosis Patient.

Clin Microbiol Infect. 2005 Sep;11(9):690-703. Review.

13.

Pseudomonas aeruginosa in cystic fibrosis is potentially serious, and more than merely a marker for disease severity.

Lenney W.

Paediatr Respir Rev. 2015 Oct;16 Suppl 1:35-6. doi: 10.1016/j.prrv.2015.07.016. Epub 2015 Sep 26. Review. No abstract available.

PMID:
26410280
14.

Pseudomonas aeruginosa infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches.

Lund-Palau H, Turnbull AR, Bush A, Bardin E, Cameron L, Soren O, Wierre-Gore N, Alton EW, Bundy JG, Connett G, Faust SN, Filloux A, Freemont P, Jones A, Khoo V, Morales S, Murphy R, Pabary R, Simbo A, Schelenz S, Takats Z, Webb J, Williams HD, Davies JC.

Expert Rev Respir Med. 2016 Jun;10(6):685-97. doi: 10.1080/17476348.2016.1177460. Epub 2016 May 13. Review.

PMID:
27175979
15.

Fluoroquinolones in the treatment of cystic fibrosis: a critical appraisal.

LeBel M.

Eur J Clin Microbiol Infect Dis. 1991 Apr;10(4):316-24. Review.

PMID:
1907546
16.

Fluoroquinolones in the treatment of cystic fibrosis.

Høiby N, Pedersen SS, Jensen T, Valerius NH, Koch C.

Drugs. 1993;45 Suppl 3:98-101. Review.

PMID:
7689459

Supplemental Content

Support Center